Nektar Therapeutics (NASDAQ:NKTR) shares traded up 1.5% during trading on Monday . The company traded as high as $86.11 and last traded at $84.06. 899,298 shares were traded during trading, a decline of 69% from the average session volume of 2,943,831 shares. The stock had previously closed at $85.30.
A number of research analysts have commented on the stock. Canaccord Genuity set a $94.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, May 11th. HC Wainwright set a $125.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Sunday. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Friday, May 11th. ValuEngine raised shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, BidaskClub downgraded shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, April 18th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $79.50.
The firm has a market cap of $14.62 billion, a price-to-earnings ratio of -149.00 and a beta of 1.79. The company has a current ratio of 4.16, a quick ratio of 4.03 and a debt-to-equity ratio of 4.21.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Nektar Therapeutics had a negative net margin of 40.07% and a negative return on equity of 202.41%. The firm had revenue of $38.02 million during the quarter, compared to the consensus estimate of $35.59 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. The firm’s quarterly revenue was up 53.7% on a year-over-year basis. equities analysts forecast that Nektar Therapeutics will post 3.38 EPS for the current year.
In other news, SVP Stephen K. Doberstein sold 160,000 shares of the firm’s stock in a transaction dated Monday, April 9th. The shares were sold at an average price of $93.06, for a total value of $14,889,600.00. Following the sale, the senior vice president now directly owns 127,394 shares in the company, valued at approximately $11,855,285.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO John Nicholson sold 220,144 shares of the firm’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $99.27, for a total transaction of $21,853,694.88. Following the completion of the sale, the chief operating officer now owns 267,657 shares in the company, valued at $26,570,310.39. The disclosure for this sale can be found here. Insiders sold a total of 827,019 shares of company stock worth $75,562,898 over the last 90 days. Company insiders own 5.44% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Advisor Partners LLC acquired a new stake in Nektar Therapeutics in the 4th quarter worth approximately $393,000. Carillon Tower Advisers Inc. acquired a new stake in Nektar Therapeutics in the 4th quarter worth approximately $43,024,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Nektar Therapeutics in the 4th quarter worth approximately $219,000. Teachers Advisors LLC boosted its stake in Nektar Therapeutics by 38.0% in the 4th quarter. Teachers Advisors LLC now owns 930,424 shares of the biopharmaceutical company’s stock worth $55,565,000 after purchasing an additional 256,078 shares in the last quarter. Finally, Aperio Group LLC boosted its stake in Nektar Therapeutics by 14.6% in the 4th quarter. Aperio Group LLC now owns 49,830 shares of the biopharmaceutical company’s stock worth $2,976,000 after purchasing an additional 6,345 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.